The commonest immunotherapeutic approach is use of immune checkpoint inhibitors (ICI), especially the combination of oncolytic virus T‐Vec and PD‐1 ICI pembrolizumab17 or CTLA‐4 ICI ipilimumab18 for advanced melanoma. The gene discussed is CTLA4; the disease is melanoma.